NCT00675077

Brief Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started May 2008

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

May 6, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 8, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

January 5, 2009

Status Verified

January 1, 2009

Enrollment Period

2 years

First QC Date

May 6, 2008

Last Update Submit

January 2, 2009

Conditions

Huntington Disease

Keywords

Akinetic-Rigid Variant of Huntington DiseaseChorea, Chronic Progressive Hereditary (Huntington)Chronic Progressive Hereditary Chorea (Huntington)Huntington ChoreaHuntington Chronic Progressive Hereditary ChoreaHuntington Disease, Akinetic-Rigid VariantHuntington Disease, JuvenileHuntington Disease, Juvenile-Onset

Outcome Measures

Primary Outcomes (1)

  • Treatment of people with HD

    2 years

Secondary Outcomes (1)

  • Rehabilitation of people with HD

    2 Years

Study Arms (1)

1

EXPERIMENTAL

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Radiation: Far Infrared Radiation

Interventions

Far Infrared RadiationRADIATION

Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Also known as: Far Infrared Radiation (5μm to 20μm wavelength)
1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • People with HD

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

Huntington DiseaseChorea

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaDyskinesiasMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCognition DisordersNeurocognitive DisordersMental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 6, 2008

First Posted

May 8, 2008

Study Start

May 1, 2008

Primary Completion

May 1, 2010

Study Completion

June 1, 2010

Last Updated

January 5, 2009

Record last verified: 2009-01

Locations

CA(1)